Prof. Yibin Feng | Liver Cancer | Lifetime Achievement Award

Prof. Yibin Feng | Liver Cancer | Lifetime Achievement Award

The University of Hong Kong | Hong Kong

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS 

Professor Yibin Feng began his academic journey with a focus on traditional medicine and its applications in modern healthcare. His early studies laid a strong foundation in the integration of ancient practices with contemporary scientific research. His education likely included rigorous training in both the theoretical and practical aspects of herbal medicine, setting the stage for his future research.

🌟 PROFESSIONAL ENDEAVORS 

Currently, Professor Feng is associated with The University of Hong Kong, where he specializes in liver cancer treatment using Chinese herbal formulas. His professional role involves leading research projects, mentoring students, and collaborating with other experts in the field to advance the understanding and application of traditional Chinese medicine in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LIVER CANCER

Professor Feng’s research primarily concentrates on leveraging Chinese herbal formulas for treating liver cancer. His work explores how traditional remedies can be integrated into modern cancer treatments, aiming to enhance therapeutic outcomes and improve patient quality of life. His contributions include:

  • Investigating the efficacy of herbal formulas in liver cancer treatment.
  • Conducting clinical trials to validate the therapeutic potential of these traditional remedies.
  • Exploring the mechanisms through which these herbal treatments impact cancer cells and patient health.

🌍 IMPACT AND INFLUENCE

Professor Feng’s research has significantly influenced the field of integrative oncology. By bridging traditional Chinese medicine with modern cancer therapies, his work has opened new avenues for treatment strategies that blend ancient wisdom with cutting-edge science. His influence extends through:

  • Enhanced understanding of herbal medicine’s role in cancer treatment.
  • Development of new therapeutic approaches incorporating traditional remedies.
  • Increased acceptance and integration of alternative medicine in mainstream cancer care.

📈 ACADEMIC CITES 

Professor Feng’s research is well-cited within the academic community, reflecting the impact and importance of his work. His publications contribute valuable insights into the application of herbal medicine in cancer treatment, and his findings are referenced by researchers and practitioners seeking to explore or validate similar approaches.

🏆 LEGACY AND FUTURE CONTRIBUTIONS 

Professor Feng’s legacy is defined by his dedication to merging traditional and modern medical practices. His future contributions are expected to further advance the integration of Chinese herbal medicine into contemporary oncology, potentially leading to innovative treatments and improved patient outcomes. His ongoing research and collaborations will likely continue to shape the field and inspire future scholars and practitioners.

🌟 CONCLUSION 

Professor Yibin Feng’s work exemplifies the successful integration of traditional Chinese herbal medicine with modern cancer treatment methodologies. His early academic pursuits laid a robust foundation for his current research, which focuses on leveraging herbal formulas to treat liver cancer. His professional endeavors at The University of Hong Kong underscore his commitment to advancing this field through innovative research and clinical applications.

 

📊🔬NOTABLE PUBLICATION:

 

  • Title: CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress
    Authors: Lu, Y., Chan, Y.-T., Wu, J., Feng, Y., Wang, N.
    Year: 2023

 

  • Title: Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
    Authors: Chan, Y.-T., Wu, J., Lu, Y., Feng, Y., Wang, N.
    Journal: Molecular Cancer
    Year: 2024

 

  • Title: PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer
    Authors: Wu, J., Tan, H.-Y., Chan, Y.-T., Feng, Y., Wang, N.
    Journal: Journal of Experimental and Clinical Cancer Research
    Year: 2024

 

  • Title: Updated Insights into Probiotics and Hepatobiliary Diseases
    Authors: Xu, X., Zhang, C., Tang, G., Wang, N., Feng, Y.
    Journal: Biomedicines
    Year: 2024

 

  • Title: Effects and mechanisms of anti-diabetic dietary natural products: an updated review
    Authors: Cheng, J., Li, J., Xiong, R.-G., Feng, Y., Gan, R.-Y.
    Journal: Food and Function
    Year: 2024